Most studies showed that the use of anti-inflammatory treatment, including the disease-modifying anti rheumatoid drugs (DMARDs), reduce the rate of bone loss in RA patients [28,29]; Wijbrandts et al. conducted a prospective study about the effect of tumor necrosis factor (TNF)-alpha blocker (adalimumab) in RA patients. The gene discussed is TNF; the disease is rheumatoid arthritis.